Fulyzaq approved for ART-related diarrhea in HIV/AIDS

Fulyzaq approved for ART-related diarrhea in HIV/AIDS
The first medication to treat diarrhea in people with HIV/AIDS who take antiretroviral drugs has been approved by the U.S. Food and Drug Administration.

(HealthDay)—The first medication to treat diarrhea in people with HIV/AIDS who take antiretroviral drugs has been approved by the U.S. Food and Drug Administration.

Fulyzaq (crofelemer) is sanctioned for people whose diarrhea is not caused by an infection or but by the antiretroviral drugs used to combat HIV/AIDS, the FDA said in a news release. The drug is derived from the red sap of the Croton lechleri plant.

Fulyzaq's safety and effectiveness were evaluated in a clinical study involving 374 people who were HIV-positive, on stable drug therapy, and who had had diarrhea for one month or longer. About 17.6 percent of people who took Fulyzaq had a positive "clinical response," compared with a positive response among 8 percent of people who took a placebo.

All participants in the study were tested to confirm that their symptoms were not caused by an infection or , the FDA said. Common side effects to Fulyzaq's use were upper , bronchitis, cough, flatulence, and an increase in the liver enzyme bilirubin.

The drug is distributed by Salix Pharmaceuticals, based in Raleigh, N.C.

More information: More Information

add to favorites email to friend print save as pdf

Related Stories

Xeljanz approved for rheumatoid arthritis

Nov 07, 2012

(HealthDay)—Xeljanz (tofacitinib) has been approved by the U.S. Food and Drug Administration to treat symptoms of rheumatoid arthritis (RA) among people who can't tolerate, or haven't been helped by, the drug methotrexate.

Afinitor approved for advanced breast cancer

Jul 23, 2012

(HealthDay) -- Afinitor (everolimus) has been approved in combination with the drug exemestane to treat postmenopausal women with advanced hormone-receptor positive, HER2-negative breast cancer, the U.S. Food ...

Gattex approved for short bowel syndrome

Dec 22, 2012

(HealthDay)—Gattex (teduglutide) has been approved by the U.S. Food and Drug Administration to treat nutritional problems caused by short bowel syndrome.

US approves new HIV drug

May 21, 2011

The US Food and Drug Administration on Friday approved a new drug, Edurant, to fight HIV in combination with other antiretrovirals already on the market.

Recommended for you

Determine patient preferences by means of conjoint analysis

Jul 29, 2014

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

User comments